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  MONITORING OF THERMAL AND OXIDATION 
STABILITY OF SODIUM PICOSULFATE BY 
MODIFIED RP-HPLC METHOD 
A selective, precise and stability-indicating, modified high performance liquid 
chromatographic method for the analysis of sodium picosulfate both as a bulk 
drug and in formulations was developed and validated. As the method could 
effectively separate the drug from its degradation product, it can be employed as 
a stability-indicating one. The chromatographic separation was achieved on a 
ZORBAX Eclipse XDB C-18 analytical column. The mobile phase consisted of 
phosphate buffer (pH 7):acetonitrile (85:15 v/v). The absorbance was monitored 
with a DAD detector at 263 nm. The flow rate was 1.5 mL min
-1. Statistical ana-
lysis proved the method is repeatable, selective, and accurate for estimation of 
sodium picosulfate in the presence its degradation product. Forced degradation 
studies were performed on bulk sample of sodium picosulfate using heat (25, 40, 
60 and 80 °C) and oxidation (0.1, 0.5 and 1% v/v hydrogen peroxide). The pro-
posed method was successfully applied, with excellent recovery, to the analysis 
of a pharmaceutical formulation (Sodium picosulfate, Zdravlje-Actavis, Serbia). 
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Sodium picosulfate 4,4’-(2-pyridylmethylene)di-
phenyl bis(hydrogen sulfate) disodium is a medicine 
known as a stimulant laxative [1]. After being taken 
orally, it is activated by the bacteria naturally present 
in the large intestine. It then stimulates nerve endings 
in the intestinal wall. These nerves make the muscles 
in the intestine and rectum contract more often and 
with more force, a process known as peristalsis. This 
moves the contents of the intestine along so that the 
bowel can be emptied, and hence relieves constipa-
tion. Sodium picosulfate is also used to stimulate the 
emptying of the bowel before surgery, childbirth or 
medical investigation of the gut. 
Early detection of laxative abuse may eliminate 
the costly tests these patients would undergo other-
wise. Previous screens of laxative in urine have been 
described in the literature based on TLC [2-5], 
GLC/MS [6] and HPLC with diode array detection [7]. 
A modified procedure for the analytical control of a 
pharmaceutical formulation Evacoul
® (Laboratorios 
Almiral, St. Andrey de la Barca, Spain) by capillary 
electrophoresis is proposed. It allows the simul-
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taneous determination of the major compounds in the 
formulation: the active compound (sodium picosulfa-
te) and preservative (methylparaben) and the degra-
dation products of the preservative, which slowly de-
grades by hydrolysis or by transesterification with sor-
bitol (sweetener in excess in the formulation). 
The HPLC is still not the official method in any 
pharmacopoeia for the analysis of sodium picosulfate 
[8,9]. The validated HPLC method for analysis sodium 
picosulfate in the presence of impurities was pro-
posed in a new USP’s Pending Standards monograph 
[10]. But that monograph is not a USP-NF mono-
graph. Using that procedure we could not separate 
sodium picosulfate (Sodium picosulfate, Zdravlje-Ac-
tavis, Serbia) from degradation products obtained du-
ring forced degradation. 
Therefore, the aim of this work was to develop 
and validate a modified RP-HPLC feasible and spe-
cific analytical procedure. The procedure should be 
suitable for the application in a drug quality control or 
regulatory laboratory analysis of sodium picosufate in 
the presence of its degradation product (Fig. 1). The 
analysis of the degradation product obtained during 
the thermal degradation at different temperatures and 
oxidation in H2O2 solutions with various concentra-
tions, at room temperature was presented in this pa-
per. The developed analytical method was validated 
as per International Conference on Harmonization I. SAVIC et al.: MONITORING OF THERMAL AND OXIDATION STABILITY…  CI&CEQ 16 (1) 102−110 (2010) 
 
104 
guidelines [11] and Serbian requirements [12]. Sta-
tistical tests were performed on validation data [13]. 
The validation consists of testing the method selec-
tivity towards components and the assessment of the 
method precision, trueness and accuracy [14,17] at 
different concentration levels over the range investi-
gated, as well as the confirmation of the limit of quan-
titation (LOQ) and the method linearity [14-16]. The 
adaptation of the proposed procedure for the analysis 
of the available dosage form, including the expired 
ones, is also an important task in order to solve pro-
blems encountered in the quality control. 
EXPERIMENTAL 
Samples. Standard substances of sodium pico-
sulfate and 4-[(pyridin-2-yl)(4-hydroxyphenyl) methyl]-
phenyl sodium sulfate, as well as sodium picosulfate 
tablets were kindly supplied by Zdravlje-Actavis, Les-
kovac. Each tablet is claimed to contain 5 mg of so-
dium picosulfate. 
Reagents. All chemicals used were of analytical 
grade and deionized water was of HPLC grade. Di-
sodium hydrogen phosphate, potassium dihydrogen 
phosphate and acetonitrile for HPLC were obtained 
from Merck, N.Y.C., U.S.A. 
Apparatus. The method development was per-
formed with an Agilent 1100-Series HPLC system 
(Agilent Technologies, USA) consisting of an Agilent 
1100-Series variable wavelength UV detector and 
Agilent 1100-Series auto-sampler using a 50 μL sam-
ple loop (The Faculty of Technology, Leskovac). The 
system was controlled and data analyses were per-
formed with the Agilent HPLC Data Analysis software. 
The reproducibility were performed with another LC 
system consisting of an Agilent 1100-Series binary 
pump and Agilent 1100-Series DAD detector (Zdrav-
lje-Actavis, Leskovac). The detector was set at 263 
nm and the peak areas were integrated automatically 
by the computer using the Agilent HPLC Data Analy-
sis software program. The separation was carried out 
at 25 °C using a ZORBAX Eclipse XDB-C18 column 
(4.6 mm×250 mm, 5 μm), Agilent Technologies, USA. 
All the calculations concerning the quantitative analy-
sis were performed with the external standardization 
by measuring the peak areas. 
Chromatographic conditions. RP-HPLC analysis 
was performed by isocratic elution with a flow rate of 
1.5 mL min
-1. A mobile phase consisting phosphate 
buffer in water:acetonitrile (85:15 v/v). Phosphate buf-
fer: 0.5 g disodium hydrogen phosphate and 0.301 g 
potassium dihydrogen phosphate transfered to a 1 L 
flask and dissolved in water. All solvents were filtered 
through a 0.45 μm millipore filter. The volumes of 50 
μL of the solutions and samples prepared were injec-
ted into the column. Quantification was effected by 
measurement at 263 nm as established from the 3-D 
chromatogram. Throughout the study, the suitability of 
the chromatographic system was monitored by calcu-
lating the capacity factor (k), the selectivity (α) and 
peak asymmetry (As). 
Procedures 
To prepare the solutions of different concentra-
tions, aliquots of the stock solution were transferred 
into a series of 10 mL standard volumetric flasks and 
the volumes were made with the respective media. 
Ten different concentrations were prepared in the ran-
ge of 10-100 g mL
-1 of sodium picosulfate in a mobile 
phase for a standard curve. The final concentrations 
of sodium picosulfate in the samples were calculated 
by comparing the sample and standard peak area ob-
tained with the average of three injections of standard 
solutions. 
Stability study. In order to monitor the thermal 
stability, 5 mg of sodium picosulfate was dissolved in 
a 100 mL volumetric flask in the mobile phase. This 
solution was transferred into another clean dry conical 
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flask and refluxed in a thermostatically controlled wa-
ter bath at 25, 40, 60 and 80 °C for 60 min. 1 mL of 
samples was taken. To monitor the oxidation stability, 
5 mg of sodium picosulfate in 0.1, 0.5 and 1.0% H2O2 
was dissolved in a 100 mL volumetric flask and com-
pleted to the mark with the same solvent. This solu-
tion was transferred into another clean dry conical flask 
and refluxed in a thermostatically controlled water 
bath at 25 °C for 30 min. 
The accuracy of the method is the closeness of 
the measured value to the true value for the sample. 
To determine the accuracy of the proposed method, 
different levels of drug concentrations - lower concen-
tration (LC, 80%), intermediate concentration (IC, 
100%) and higher concentration (HC, 120%) were 
prepared from independent stock solutions and ana-
lyzed (n = 10). The accuracy was assessed as the 
percentage relative error and mean % recovery (Tab-
le 1). To provide an additional support to the accuracy 
of the developed assay method, a standard addition 
method was employed which involved the addition of 
different concentrations of the pure drug (10, 20 and 
30 μg mL
-1) to a known preanalyzed formulation sam-
ple and the total concentration was determined using 
the proposed methods (n = 10). The % recovery of 
the added pure drug was calculated as %recovery = 
= [(ct-cs)/ca]×100, where ct is the total drug concen-
tration measured after the standard addition; cs, drug 
concentration in the formulation sample; ca, drug con-
centration added to formulation (Table 2). 
 
The reproducibility was determined by using dif-
ferent levels of drug concentrations (the same con-
centration levels taken in the accuracy study), pre-
pared from independent stock solutions and analyzed 
(n = 10) (Table 1). Inter-day, intra-day and inter-ins-
trument variation were studied to determine the inter-
mediate precision of the proposed analytical method. 
Different levels of drug concentrations in triplicates 
were prepared three different times in a day and stu-
died for intra-day variation. The same procedure was 
followed for three different days in order to study the 
inter-day variation (n = 10). One set of different levels 
of the concentrations was reanalyzed using another 
HPLC Agilent 1100-Series system, by proposed me-
thods to study inter-instrument variation (n = 10). The 
percent relative standard deviation (% RSD) of the 
predicted concentrations from the regression equation 
was taken as precision (Table 3). The precision stu-
dies were also carried out by using the real samples 
of sodium picosulfate in a similar way to a standard 
solution to prove the usefulness of the method. 
Robustness. To determine the robustness of the 
developed method, experimental conditions were pur-
posely altered. To study the effect of the flow rate on 
the resolution, it was changed by 0.5 units from 1 to 2 
mL min
-1, while the other mobile phase components 
were held constant as per the method. The effect of 
the column temperature on resolution was studied at 
20 and 30 °C instead of 25 °C while the other mobile 
phase components were held constant as per the me-
thod. 
Table 1. Accuracy and the precision data for the developed method (n = 10) 
Level 
Predicted concentration (μg mL
-1)
 
Mean recovery, %  Accuracy, % 
Mean (±SD) %  RSD 
LC (40 μg mL
-1)  40.23 ± 0.33  0.81  100.57  0.57 
IC (50 μg mL
-1)  50.21 ± 0.34  0.67  100.42  0.42 
HC (60 μg mL
-1)  59.92 ± 0.32  0.53  99.87  -0.13 
Table 2. Standard addition of sodium picosulfate (50 μg mL
-1) for accuracy (n = 10) 
Pure drug added, μg mL
-1  Total drug found(±SD), μg mL
-1 %Recovery  (±RSD) 
0  50.21 ± 0.34  100.42 ± 0.67 
10  59.92 ± 0.32  99.87 ± 0.53 
20  70.35 ± 0.45  100.50 ± 0.64 
30  79.87 ± 0.42  99.84 ± 0.53 
Table 3. System precision study (n = 10) 
Concentration, μg mL
-1 
Estimated concentration, intra-day reproducibility ± RSD, n = 10  Intra-instrument repro-
ducibility ± RSD, n = 10
 
Day 1  Day 2  Day 3 
40  39.65 (0.81)  39.94 (0.67)  40.48 (0.51)  38.96 (0.89) 
50  49.85 (0.05)  50.32 (0.21)  49.88 (0.08)  50.35 (1.41) 
60  60.55 (0.18)  60.51 (0.84)  60.15 (0.08)  60.34 (1.55) I. SAVIC et al.: MONITORING OF THERMAL AND OXIDATION STABILITY…  CI&CEQ 16 (1) 102−110 (2010) 
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Procedure for tablets. A total of 20 tablets of stu-
died pharmaceutical preparation (sodium picosulfate, 
Zdravlje-Actavis, Serbia) containing sodium picosul-
fate were weighed and finely powdered using a pestle 
and mortar. An accurately weighed quantity of the re-
sulting powder, equivalent to 5 mg (weight of one tab-
let) of sodium picosulfate was dissolved in 10 mL of 
methanol. Then it was filtered directly into a 10 mL 
standard volumetric flask. For HPLC determination, 
aliquots (1 mL) of sodium picosulfate were taken and 
suitably diluted with the mobile phase in order to get a 
50 g mL
-1 concentration and the samples were injec-
ted into the chromatograph. 
Comparative method. The employed procedures 
for the comparative method (potentiometric titration) 
is described in the European Pharmacopoeia [8]. 
RESULTS AND DISCUSSION 
HPLC Analysis 
The main target of the chromatographic method 
was to achieve the separation of sodium picosulfate 
and its degradation product (Imp-A) by using different 
stationary phases like C18, C8 and cyano, different 
mobile phases containing buffers like phosphate, sul-
fate and acetate with different pH (7-10) and using or-
ganic modifiers like methanol in the mobile phase. 
The chromatographic separation was achieved on a 
ZORBAX Eclipse XDB-C18 column (4.6 mm×250 mm), 
with a particle size of 5 μm. Satisfactory separation of 
used standards was obtained with a mobile phase 
consisting of 0.05% disodium hydrogen phosphate 
and 0.0301% potassium dihydrogen phosphate in 
water:acetonitrile (85:15 v/v). The optimum pH was 7 
because at pH values higher than 7, a somewhat 
larger peak tailing and inferior resolution resulted. If 
methanol was used instead of acetonitrile, the sepa-
ration of sodium picosulfate and the impurity was also 
with an unsatisfactory resolution. The maximum ab-
sorption of sodium picosulfate was detected at 263 
nm and this wavelength was chosen for the analysis. 
The developed RP-HPLC method was found to be 
specific for sodium picosulfate and its degradation 
product. A corresponding HPLC chromatogram of 
mixture standards sodium picosulfate and its impurity 
A is shown in Fig. 2. The HPLC chromatogram of its 
products after thermal degradation at 40 °C and oxi-
dation (0.5 % H2O2), recorded at 263 nm, is shown in 
Fig. 3. The obtained compounds during thermal de-
gradation and oxidation were identified by using ade-
quate standards. At retention time of 1.811 min so-
dium picosulfate was identified and at 1.274 min its 
thermal and oxido degradation product 4-[(pyridin-2- 
-yl)(4-hydroxyphenyl) methyl]phenyl sodium sulfate 
(Fig. 3) was noticeable. 
Chromatographic parameters, such as the effi-
ciency column and peak asymmetry were reconsi-
dered for the sodium picosilfate standard (Fig. 2). Ac-
cording to the obtained value of the number of theore-
tical plate (N = 1144), the conclusion is that the effi-
ciency column is satisfactory (HETP = 0.2184). The 
asymmetry peak value of 0.368 indicates that the 
peak is not ideally symmetric, that is, it is not Gauss’s 
peak. Having in mind that Wab < Wbc, this means that 
 
Figure 2. The HPLC chromatogram at 263 nm of mixture standards sodium picosulfate (tr = 1.811 min) and 
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there is a certain interaction between the stationary 
phase and the investigated component. The value of 
selectivity (α) was 1.77. In the optimized conditions, 
sodium picosulfate and its impurity A were well sepa-
rated with a resolution greater than 2.5. 
The good linearity was obtained between the 
peak areas and the concentrations. The linear regres-
sion equation (Eq. (1)), obtained with a regression 
coefficient (r) of 0.9933, was: 
005 . 294 ) ( 35 . 21395
1
263 + × =
− mL g c A μ  (1) 
The linearity range was obeyed in the range of 
decade 10-100 μg mL
-1. The chromatogram of sodium 
picosulfate was not changed in the presence of com-
mon excipients used in the pharmaceutical prepara-
tions. The chromatogram of the pure drug sample was 
matched with the formulation samples in a mobile 
phase. The calculated t-value of 1.468 was found to 
be less than that of the tabulated t-value (t = 2.225). 
Therefore, the proposed analytical method is specific 
and selective for the drug. The linearity range for so-
dium picosulfate estimation was found to be 10-100 
μg mL
-1 (r = 0.9933). Goodness of the fit of the regres-
sion equations was supported by high regression co-
efficient values. 
The accuracy of the method was checked by de-
termining recovery values. Series of solution were 
made containing 80, 100 and 120% of sodium pico-
sufate regarding the declared content. The accuracy 
ranged from 40 to 60 μg mL
-1 (Table 1). The excellent 
mean % recovery values, close to 100%, and their 
low standard deviation values (SD < 1.0) represent 
high accuracy of the analytical methods. 
The validity and reliability of the proposed me-
thods were further assessed by recovery studies via 
the standard addition method. The mean %recoveries 
(±RSD) for the concentration of 50 μg mL
-1 are show-
ed in Table 2. These results revealed that any small 
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change in the drug concentration in the solutions 
could be accurately determined by the proposed ana-
lytical methods. 
The precision was determined by studying the 
repeatability and the intermediate precision. Repea-
tability (±RSD) ranged from 40 to 60 μg mL
-1 (Table 
3). The repeatability results indicated the precision 
under the same operating conditions over a short in-
terval of time and the inter-assay precision. The inter-
mediate precision expresses within-laboratory varia-
tions in different days and in different instruments. In 
the intermediate precision study, ±RSD values were 
not more than 2.0% in all the cases. RSD values found 
for the proposed analytical method were well within 
the acceptable range indicating that the method has 
the excellent repeatability and intermediate precision. 
The limits of detection (LOD) and quantification 
(LOQ) were evaluated using the following equations 
[18-21]: 
b
S
LOQ
b
S
LOD
0
0
10
3 . 3
=
=
 
were S 0  is the standard deviation of the calibration 
line and b is the slope. They were found to be 0.086 
and 0.258 μg mL
-1, respectively.  
Robustness. In all the deliberate varied chroma-
tographic conditions (flow rate and column tempera-
ture) no significant change in the assay value was ob-
served. The system suitability parameters like tailing 
and the RSD values are well within the limits. Tailing 
was 0.412 and 0.332 and RSD was 0.8 and 0.6% for 
flow rate and column temperature variations which 
confirms the robustness of the developed method. 
Applicability of the proposed method. The pro-
posed method was applied for the determination of 
sodium picosulfate in pharmaceutical formulations 
using a direct calibration curve. As it can be seen in 
Table 4, the results obtained for this method are in 
accordance with the official potentiometric titration. 
The results of the proposed method were statistically 
compared with this of the official method using a point 
hypothesis test [22,23]. Table 4 shows that the 
calculated F and t values at the 95% confidence level 
are less than the theoretical ones, confirming no sig-
nificant differences between the performance of the 
proposed and the official method. 
Stability study 
The purpose of the stability testing was to inves-
tigate how the quality of a drug product changes with 
time under the influence of environmental factors. 
Since the temperature and oxidation-induced degra-
dation of the drug may have a negative impact on the 
quality, safety and effectiveness of pharmacotherapy, 
the research focused on this point is definitely reason-
nable. 
Sodium picosulfate was exposed to temperature 
and oxidation. The percentage of the degradation pro-
duct was observed every 5 min for 30 and for 60 min. 
The results are given in Tables 5 and 6. The obtained 
results showed that sodium picosulfate is a relatively 
thermal and oxide stable compound. 
CONCLUSION 
On the bases of the experimental results, the 
proposed method is suitable for the simultaneous 
qualitative and quantitative determination of sodium 
picosulfate and a related substance in pharmaceutical 
formulations. The method provides great sensitivity, 
adequate linearity and repeatability. It is also quicker 
and simpler for the sample preparation than already 
offered procedures. It was shown that sodium pico-
Table 4. Determination of sodium picosulfate by the HPLC and the official methods (potentiometric titration) 
Compound Taken,  μg mL
-1 
Sodium picosulfate found 
by HPLC
a 
x±SD, μg mL
-1 
± RSD
a Recovery
a, % F Value
b  t Value
b 
Potentiometric titration
x±SD, μg mL
-1 
Sodium picosulfate  50  51.20±0.02 2.16  102.41  1.36  0.609  51.30±0.01 
aData are based on the average obtained from five determinations; 
btheoretical F value (ν1 = 4, ν2 = 4) and t value (ν = 8) at the 95% confidence level are 
6.39 and 2.306, respectively 
Table 5. Thermal degradation product (%)
 
Temperature, °C 
Time of exposure, min 
0  5  10 15 20 30 60 
25  -  0.010 0.023 0.039 0.057 0.078 0.084 
40  -  0.014 0.027 0.045 0.068 0.094 0.110 
60  -  0.015 0.031 0.057 0.076 0.107 0.130 
80  -  0.018 0.038 0.064 0.084 0.118 0.160 I. SAVIC et al.: MONITORING OF THERMAL AND OXIDATION STABILITY…  CI&CEQ 16 (1) 102−110 (2010) 
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sulfate is a relatively thermal stable and oxide stable 
compound. As the main decomposition product, impu-
rity A was found by RP-HPLC. The chromatogram 
obtained after oxide degradation of sodium picosul-
fate shows that some other impurity is formed. A fur-
ther study is necessary for the identification of this de-
composition product. 
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Table 6. Oxide degradation product (% area) 
Concentration (% area) 
Time of exposure, min 
0 5  10  15  20 30 
0.1 -  0.33  0.54  0.88  1.23  1.73 
0.5 -  0.50  1.00  1.38  1.82  2.10 
1 -  0.83  1.21  1.86  2.21  2.84 
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NAUČNI RAD 
  PRAĆENJE TERMO I OKSIDO-STABILNOSTI NATRI-
JUM-PIKOSULFATA MODIFIKOVANOM 
RP-HPLC METODOM 
Razvijena je i validovana selektivna, precizna i stabilna modifikovana HPLC metoda za 
analizu natrijum-pikosulfata, kao čiste supstance i u obliku formulacija. Za efikasno od-
vajanje aktivne supstance od njenog degradacionog produkta mora se razviti stabilna 
metoda. Hromatografsko odvajanje postignuto je na ZORBAX Eclipse XDB C-18 koloni. 
Mobilna faza sadržala je fosfatni pufer (pH 7):acetonitril (85:15 v/v). Apsorbanca je pra-
ćena DAD detektorom na 263 nm. Brzina protoka bila je 1,5 mL min
-1. Statistička analiza 
pokazuje da je metoda ponovljiva, selektivna i tačna za određivanje natrijum-pikosulfata 
u prisustvu njegovog degradacionog produkta. Ispitivanja forsirane degradacije praćena 
su na čistim uzorcima natrijum-pikosulfata korišćenjem toplote (25, 40, 60 i 80 °C) i oksi-
dacijom (0,1, 0,5 i 1% v/v vodonik-peroksid). Predložena metoda uspešno je primenjena, 
sa odličnim obnavljanjem, za analizu farmaceutske formulacije (natrijum-pikosulfat, 
Zdravlje-Actavis, Srbija). 
Ključne reči: natrijum pikosulfat; degradacija; RP-HPLC; stabilnost. 
 
 